{"id":296039,"date":"2025-02-25T00:00:00","date_gmt":"2025-02-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0013-2023-biopharma-asthma-unmet-need-unmet-need-severe-asthma-us-eu\/"},"modified":"2026-04-24T11:16:19","modified_gmt":"2026-04-24T11:16:19","slug":"unneim0013-2025-biopharma-asthma-unmet-need-unmet-need-severe-asthma-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0013-2025-biopharma-asthma-unmet-need-unmet-need-severe-asthma-us-eu\/","title":{"rendered":"Asthma &#8211; Unmet Need &#8211; Unmet Need &#8211; Severe Asthma (US\/EU)"},"content":{"rendered":"<p>Several effective anti-inflammatory agents and bronchodilators are available for controlling patients\u2019 mild or moderate asthma. However, despite the availability of <abbr title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>s (e.g., Boehringer Ingelheim\u2019s Spiriva), <abbr title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr title=\"fixed-dose combination\">FDC<\/abbr>s (e.g., <abbr title=\"GlaxoSmithKline\">GSK<\/abbr>\u2019s Trelegy, Chiesi\u2019s Trimbow), and novel biologics (e.g., AstraZeneca\u2019s Fasenra, Teva\u2019s Cinqair \/ Cinqaero, Sanofi \/ Regeneron\u2019s Dupixent, <abbr title=\"GlaxoSmithKline\">GSK<\/abbr>\u2019s Nucala), effective therapies for severe disease are still needed, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent <abbr title=\"short-acting beta2 agonist\">SABA<\/abbr> and\/or oral corticosteroid use to achieve relief. This Unmet Need report provides quantitative insights into key treatment drivers and goals and the current level of unmet need in the treatment of severe asthma, based on the perceptions of U.S. and European physicians.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals for severe asthma?<\/li>\n<li>Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies, including key inhaled therapies and biologics, perform on key treatment drivers and goals for severe asthma?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in severe asthma?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new drug for severe asthma?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p><span class=\"TextRun SCXW154805910 BCX0\" data-contrast=\"none\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW154805910 BCX0\" data-ccp-parastyle=\"Table Subtitle\" data-ccp-parastyle-defn='{\"ObjectId\":\"f09d702a-83e0-44be-a4c0-25de49833cf3|28\",\"ClassId\":1073872969,\"Properties\":[268442635,\"20\",335559739,\"0\",201342446,\"0\",201342447,\"5\",201342448,\"1\",201342449,\"0\",469777841,\"Avenir Next LT Pro Demi\",469777842,\"\",469777843,\"Avenir Next LT Pro\",469777844,\"Avenir Next LT Pro Demi\",201341986,\"0\",469769226,\"Avenir Next LT Pro Demi\",469775450,\"Table Subtitle\",201340122,\"2\",134234082,\"true\",134233614,\"true\",469778129,\"TableSubtitle\",335572020,\"19\",335551500,\"0\",335559740,\"240\",201341983,\"0\",469778324,\"Normal\"]}' style=\"-webkit-user-drag: none; -webkit-tap-highlight-color: transparent; margin: 0px; padding: 0px; user-select: text;\">Target Product Profile (TPP) simulator<\/span><\/span> tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-296039","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-therapy-areas-respiratory","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296039\/revisions"}],"predecessor-version":[{"id":575817,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296039\/revisions\/575817"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}